相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
Elisabeth J. Walsby et al.
Oncotarget (2015)
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention
Hakon Reikvam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
Erin Hertlein et al.
BLOOD (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
J. E. Lancet et al.
LEUKEMIA (2010)
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
Warren Fiskus et al.
CANCER BIOLOGY & THERAPY (2009)
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-kB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell-Mediated Cytotoxicity
Boris Boell et al.
CLINICAL CANCER RESEARCH (2009)
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Udai Banerji
CLINICAL CANCER RESEARCH (2009)
Heat Shock Protein 90-a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
H. Reikvam et al.
CURRENT CANCER DRUG TARGETS (2009)
17 AAG for HSP90 Inhibition in Cancer - From Bench to Bedside
Saad Z. Usmani et al.
CURRENT MOLECULAR MEDICINE (2009)
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Karen Lundgren et al.
MOLECULAR CANCER THERAPEUTICS (2009)
NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
Suzanne A. Eccles et al.
CANCER RESEARCH (2008)
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
Pascale Flandrin et al.
CELL STRESS & CHAPERONES (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Development and application of Hsp90 inhibitors
David B. Solit et al.
DRUG DISCOVERY TODAY (2008)
Targeting cell signaling pathways for drug discovery: An old lock needs a new key
Bharat B. Aggarwal et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
Qing Yao et al.
CLINICAL CANCER RESEARCH (2007)
17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
M Waza et al.
NATURE MEDICINE (2005)
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
RA Mesa et al.
BLOOD (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Molecular chaperones and the stress of oncogenesis
DD Mosser et al.
ONCOGENE (2004)
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3
P George et al.
CANCER RESEARCH (2004)
Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers
A Kamal et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
More than folding: localized functions of cytosolic chaperones
JC Young et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery
WB Pratt et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2003)
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Luke Whitesell et al.
CURRENT CANCER DRUG TARGETS (2003)
Overview: Translating Hsp90 Biology into Hsp90 Drugs
Paul Workman
CURRENT CANCER DRUG TARGETS (2003)
Natural Product Origins of Hsp90 Inhibitors
Yoshimasa Uehara
CURRENT CANCER DRUG TARGETS (2003)
Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90
Gabriela Chiosis et al.
CURRENT CANCER DRUG TARGETS (2003)
The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Udai Banerji et al.
CURRENT CANCER DRUG TARGETS (2003)
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
AD Basso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Molecular genetics of human leukemias: New insights into therapy
DG Gilliland
SEMINARS IN HEMATOLOGY (2002)
Hsp90 inhibitors as novel cancer chemotherapeutic agents
L Neckers
TRENDS IN MOLECULAR MEDICINE (2002)
ST1571 (Gleevec (TM)) as a paradigm for cancer therapy
BJ Druker
TRENDS IN MOLECULAR MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Modulation of Akt kinase activity by binding to Hsp90
S Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone
PA Clarke et al.
ONCOGENE (2000)
分享论文
